GTx enters global SARM accord with Merck & Co; deal includes Ph II sarcopenia drug
US drugmaker GTx and pharmaceutical major Merck & Co have signed an agreement establishing an R&D and global strategic collaboration focused on selective androgen receptor modulators (SARMs), a new class of drugs with the potential to treat age-related muscle loss (sarcopenia) as well as other musculoskeletal conditions.
This collaboration includes GTx' lead SARM drug candidate, ostarine, which is currently being evaluated in a Phase II trial for muscle loss in patients with cancer, and establishes a broad SARM cooperation under which the two firms will pool their programs and partner to discover, develop and commercialize current as well as future SARM molecules. As part of this worldwide accord, Merck will be responsible for all future costs associated with ongoing development and, if approved, commercialization of ostarine and other investigational SARMs resulting from the collaboration.
Merck to pay $40M up front
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze